AI Agents Archives

Key Considerations for AI + RWE Implementation

When AI and RWE Converge: Accelerating Evidence for Rare Disease and Innovative Therapies

BlogJuly 15, 202658Views 0Likes 0Comments

Why Evidence for Rare Disease Matters AI and real-world evidence (RWE) are reshaping the path from laboratory discovery to regulatory approval. Their convergence matters most for patients who can't afford to wait. For patients with rare diseases, waiting for treatment can mean years of uncertainty. In the United States, a rare disease is generally defined…

Systematic Literature Review vs. Meta-Analysis: Choosing the Right Approach

BlogJuly 8, 202687Views 0Likes 0Comments

SLR vs. Meta-Analysis: An Overview You've just received a research question from your stakeholders. They want to understand the effectiveness of a new therapeutic intervention across the published literature. Naturally, your next thought is: should we conduct a systematic literature review (SLR) or a meta-analysis? In healthcare and life sciences, this question sits at the…

ISPOR 2026: Hereditary Angioedema Patient Burden – Social Media Analysis

BlogJuly 2, 2026102Views 0Likes 0Comments

Hereditary Angioedema patient burden remains a significant challenge for those living with this rare, unpredictable condition, even as new treatments emerge. At MadeAi, we specialize in turning real-world patient conversations into actionable intelligence. Our latest social media listening analysis, presented at ISPOR USA 2026, reveals how HAE continues to affect daily lives while highlighting opportunities…

ISPOR 2026: AI-Augmented Reviews—A Multi-Project Analysis of Speed, Accuracy, and Workflow

BlogJune 25, 202669Views 0Likes 0Comments

AI-augmented literature reviews are transforming evidence generation across life sciences. This blog explores multi-project analysis of AI-assisted literature reviews. It examines improvements in review speed, screening accuracy, traceability, and workflow efficiency while maintaining rigorous human oversight for submission-ready outcomes. For teams in health economics and outcomes research (HEOR), regulatory affairs, and evidence generation, systematic literature…

ISPOR 2026: Identifying Drug Repurposing Opportunities with AI Literature Review

BlogJune 17, 2026100Views 0Likes 0Comments

AI-Assisted Drug Repurposing What if the next breakthrough treatment is already available today, hidden within existing drugs and waiting to be discovered? This question drives the growing field of AI-assisted drug repurposing, a smart and cost-effective strategy that looks for new therapeutic uses for approved medications. Unlike traditional drug development, which can cost billions and…

Evaluating the MadeAi Platform for Literature Screening of a Class II Medical Device

ISPOR 2026: Evaluating MadeAi for Literature Screening of a Class II Medical Device

BlogJune 9, 2026114Views 0Likes 0Comments

What is AI-assisted literature screening for Class II medical devices? AI Literature Screening for Medical Devices is the application of artificial intelligence to identify, review, classify, and prioritize scientific literature relevant to a medical device. This reduces the manual effort required for evidence generation and regulatory review workflows. For instance, AI analyzes titles, abstracts, and…

When AI and RWE Converge: Accelerating Evidence for Rare Disease and Innovative Therapies

Systematic Literature Review vs. Meta-Analysis: Choosing the Right Approach

ISPOR 2026: Hereditary Angioedema Patient Burden – Social Media Analysis

ISPOR 2026: AI-Augmented Reviews—A Multi-Project Analysis of Speed, Accuracy, and Workflow

ISPOR 2026: Identifying Drug Repurposing Opportunities with AI Literature Review

ISPOR 2026: Evaluating MadeAi for Literature Screening of a Class II Medical Device

Advanced AI Solutions for Life Sciences

Products

Services

By Need

Company

Resources

Connect With Us